This Event Has Now Run | Thank You to All Our Speakers, Sponsors and Delegates

AstraZeneca’s IL‑33 biologic Tozorakimab hits multiple Phase III successes – Meet them this September

Altesa BioSciences advances Vapendavir for rhinovirus‑triggered COPD exacerbations

GSK expands its COPD pipeline with a novel siRNA therapy (EMP‑012)

Emerging COPD treatments highlight biologics, bronchoscopic procedures & stem‑cell approaches

ReAlta’s pegtarazimod showing early promise for acute COPD exacerbations in phase 2

GSK’s Nucala gains UK backing, expanding COPD biologic access with NICE recommendation

Windward Bio and Harbour Biomed announce first Phase II dosing in SIRIUS trial for novel COPD antibody therapy

TidalSense secured $19 million to commercialise its AI-powered COPD diagnostic technology

Human Precision Cut Lung Slices as a Preclinical Platform for Development & Testing of Novel Therapeutics

11:00 am - Tuesday 15th September 2026

Human precision cut lung slices retain the cellular complexity and architecture of the native tissue in culture
Established, dynamic models of mucus hypersecretion, inflammation and fibrogenesis in precision-cut lung slices
Application of PCLS for target validation and drug testing

Lee Borthwick

Chief Executive Officer

FibroFind